Identification of Novel and Selective GPR39 Receptor Antagonists for the Treatment of Acute Myocardial Ischemia
ChemMedChem · 2026
DOI: 10.1002/cmdc.202500662 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Agostino Cianciulli und 9 weiteren Autor:innen. Beteiligte Einrichtung: Aptuit, an Evotec Company, Campus Levi-Montalcini, Via Alessandro Fleming 4, 37135, Verona, Italy. Hauptthemen laut MEDLINE: Receptors, G-Protein-Coupled, Myocardial Ischemia, Vasodilator Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Aptuit an Evotec Company.
Abstract (Originalsprache)
Following up on the discovery of multiple series of GPR39 antagonists via high‐throughput screening (HTS), appropriate hit expansion and medicinal chemistry efforts lead to the identification of potent and selective GPR39 antagonists. Among these, compound 61 emerges as the front runner of this series, demonstrating high potency, appropriate physicochemical properties governing systemic exposure, in both rat and dog, and the absence of undesired off‐target pharmacology such as cardiac ion channels (i.e., hERG, hNav1.5, and Cav1.2). In vivo evaluations show compound 61 to be a selective coronary vasodilator that reduced no‐reflow and infarct size in a rodent model of ischemia‐reperfusion. This first‐in‐class drug demonstrates the benefit of GPR39 inhibition in myocardial ischemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aptuit, an Evotec Company, Campus Levi-Montalcini, Via Alessandro Fleming 4, 37135, Verona, Italy.
- Knight Cardiovascular Institute, Oregon Health and Science University, UHN 62, Portland, OR, 97239, USA.
- Vasocardea Inc., 2010 SW Carter Lane, Portland, OR, 97239, USA.
ORCID-Profile: Sanjiv Kaul, Fabrizio Micheli
Förderung
- Aptuit an Evotec Company
Zitieren
APA
Cianciulli, A., Bernardelli, A., Faedo, S., Le, E., Methner, C., Pellacani, A., Semeraro, T., Trist, I. M. L., Kaul, S., & Micheli, F. (2026). Identification of Novel and Selective GPR39 Receptor Antagonists for the Treatment of Acute Myocardial Ischemia. ChemMedChem. https://doi.org/10.1002/cmdc.202500662
Vancouver
Cianciulli A, Bernardelli A, Faedo S, Le E, Methner C, Pellacani A, et al. Identification of Novel and Selective GPR39 Receptor Antagonists for the Treatment of Acute Myocardial Ischemia. ChemMedChem. 2026. doi:10.1002/cmdc.202500662
BibTeX
@article{Cianciulli2026,
author = {Cianciulli, Agostino and Bernardelli, Andrea and Faedo, Stefania and Le, Elisabeth and Methner, Carmen and Pellacani, Annalisa and Semeraro, Teresa and Trist, Iuni M L and Kaul, Sanjiv and Micheli, Fabrizio},
title = {Identification of Novel and Selective GPR39 Receptor Antagonists for the Treatment of Acute Myocardial Ischemia},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.202500662}
}
EUVIMED